Cancer Cachexia Market

Cancer cachexia is a wasting syndrome, which is characterized by weight loss, anorexia (loss of desire to eat), asthenia and anemia. The pathogenicity of this syndrome is multifactorial, due to a complex interaction of tumor and host factors.

According to the Cancer Cachexia Hub, approximately half of all patients with cancer experience cachexia. This rate of occurrence rises to as high as 86% in the last 1–2 weeks of life, and with 45% of patients losing more than 10% of their original body weight over disease progression.

cachexia occurs in the majority of terminal cancer patients and is responsible for the death of 22% of cancer patients [As per a Japanese study conducted by Aoyagi et al.].

Among late stage patients, cachexia affects 50–80% of cancer patients

According to a study conducted by Advani et al., “cancer cachexia impacts approximately 60% of the 1.4 million patients diagnosed with cancer in the United States each year.

For more detailed information on Cancer Cachexia Market visit: https://www.delveinsight.com/report-store/Cancer-cachexia-CC-market-insights